For the year ending 2026-03-31.
| Income Statement | 2026-03-31 | |||
|---|---|---|---|---|
| Research and development | 456,660 | |||
| Acquired in-process research and development | 0 | |||
| General and administrative | 76,242 | |||
| Total operating expenses | 532,902 | |||
| Interest income, net | 25,330 | |||
| Other (income) expense, net | 2,181 | |||
| Loss before provision for income taxes | -505,391 | |||
| Provision for income taxes | 215 | |||
| Net loss | -505,606 | |||
| Basic EPS | -2.77 | |||
| Diluted EPS | -2.77 | |||
| Basic Average Shares | 182,421,233 | |||
| Diluted Average Shares | 182,421,233 | |||
Immunovant, Inc. (IMVT)
Immunovant, Inc. (IMVT)